# Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia

> **NCT04158752** · PHASE4 · COMPLETED · sponsor: **Duke University** · enrollment: 26 (actual)

## Conditions studied

- Trigeminal Neuralgia
- Glossopharyngeal Neuralgia

## Interventions

- **DRUG:** Galcanezumab

## Key facts

- **NCT ID:** NCT04158752
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-24
- **Primary completion:** 2023-01-04
- **Final completion:** 2023-01-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158752, "Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04158752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*